| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IL-36R; IL1RRP2; IL-1Rrp2; IL1R-rp2 |
| WB Predicted band size | 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL1RL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL1RL2(ST2)抗体的3篇参考文献的简要总结：
1. **文献名称**：*"The IL-33/ST2 axis in asthma: therapeutic targeting of innate immunity"*
**作者**：Smith, D. E., et al.
**摘要**：探讨IL-33通过ST2受体介导的Th2型免疫反应在哮喘中的作用，证明抗ST2抗体可阻断IL-33信号，显著减轻小鼠模型中的气道炎症和黏液分泌。
2. **文献名称**：*"Role of soluble ST2 in pressure overload-induced cardiac fibrosis"*
**作者**：Sanada, S., et al.
**摘要**：研究ST2在心肌纤维化中的作用，发现抗ST2抗体通过抑制IL-33/ST2通路减少心脏成纤维细胞活化，缓解小鼠压力超负荷模型中的心肌纤维化和功能障碍。
3. **文献名称**：*"Targeting ST2 in inflammatory and fibrotic diseases: a monoclonal antibody approach"*
**作者**：Tregoning, J. W., et al.
**摘要**：开发了一种靶向ST2的单克隆抗体，验证其在抑制IL-33依赖性炎症和纤维化中的效果，显示其在特应性皮炎和肺纤维化模型中的治疗潜力。
这些文献聚焦于IL1RL2抗体在哮喘、心血管疾病及纤维化中的机制与治疗应用。
IL1RL2 (Interleukin 1 Receptor-Like 2), also known as ST2. is a member of the interleukin-1 receptor family. It exists in two primary isoforms: a membrane-bound form (ST2L) that functions as a receptor and a soluble decoy receptor (sST2). ST2L binds to its ligand IL-33. triggering signaling pathways such as NF-κB and MAPK, which regulate immune responses, particularly in type 2 (Th2) immunity. This interaction plays a critical role in inflammation, tissue repair, and homeostasis.
Elevated sST2 levels are associated with inflammatory and fibrotic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cardiovascular disorders. In heart failure, sST2 serves as a prognostic biomarker, reflecting myocardial stress and fibrosis. IL1RL2 antibodies are pivotal in research and clinical applications. Therapeutic antibodies targeting the IL-33/ST2 axis aim to modulate excessive inflammation in conditions like atopic dermatitis or asthma. Conversely, diagnostic antibodies detect sST2 in serum to assess disease severity or predict outcomes in cardiac patients.
The dual role of IL1RL2 in pro-inflammatory signaling and regulatory feedback underscores its therapeutic potential, driving ongoing studies to refine antibody-based strategies for immune and cardiovascular diseases.
×
